ACELYRIN, Inc.
SLRNHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | |
|---|---|---|---|
| Revenue | — | — | — |
| Operating income | −$316.3M | −$422.1M | −$69.2M |
| Net income | −$248.2M | −$381.6M | −$64.8M |
| Total assets | $491.1M | $742.7M | $319.9M |
| Total liabilities | $32.8M | $86.4M | $26.2M |
| Equity | $458.3M | $656.3M | −$102.9M |
| EPS (diluted) | $-2.50 | $-5.43 | $-41.59 |
| Shares out. | 98.4M | 97.9M | 2.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- −54.2%
- Return on assets
- −50.5%
- Return on capital (ROCE)
- −68.1%
- Liabilities / assets
- 6.7%
- Debt / equity
- 0.07×
- Book value / share
- $4.66
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- 11.50safe
- Accruals / assets
- 11.3%high accruals
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 warning● 2 good- Negative operating cash flow
- High accruals — earnings-quality risk
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Trium Capital LlpActivist (13D)May 27, 2025
- Tang Capital Management LlcActivist (13D)May 23, 2025
- Access Industries Management, LlcActivist (13D)May 23, 2025
- Ayurmaya Capital Management Company, LpPassive (13G)May 23, 2025
- Madison Avenue Partners, LpActivist (13D)Apr 30, 2025
- T. Rowe Price Investment Management, Inc.Passive (13G)Mar 7, 2025
- Citadel Advisors LlcPassive (13G)Feb 14, 2025
- Integrated Core Strategies (Us) LlcPassive (13G)Feb 10, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ayurmaya Capital Management Company, LpDirector | May 21, 2025 | D | 9.3M | $0.00 |
| Kim MinaOfficer — Chief Executive Officer | May 21, 2025 | Grant | 89,526 | — |
| Murugan AmarOfficer — Chief Legal Officer | May 21, 2025 | D | 121,587 | — |
| Seidenberg Beth CDirector | May 21, 2025 | D | 60,000 | — |
| Mpofu ShephardOfficer — Chief Medical Officer | May 21, 2025 | D | 121,789 | — |
| Gosebruch Henry ODirector | May 21, 2025 | D | 50,000 | — |
| Machado PatrickDirector | May 21, 2025 | D | 14,675 | — |
| Svoronos DawnDirector | May 21, 2025 | D | 15,000 | — |
| Becker Daniel J.Director | May 21, 2025 | D | 2,999 | — |
| Kim MinaOfficer — Chief Executive Officer | May 15, 2025 | Grant | 30,851 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2025 | 4.2M | 3.9 | +18.9% |
| Apr 30, 2025 | 3.6M | 5.7 | -3.4% |
| Apr 15, 2025 | 3.7M | 3.2 | +1.2% |
| Mar 31, 2025 | 3.6M | 4.8 | -22.1% |
| Mar 14, 2025 | 4.7M | 3.2 | +8.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMay 21, 2025
- Shareholder voteMay 19, 2025
- Entered a material agreement · Regulation FD disclosureApr 21, 2025
- Entered a material agreement · Modified shareholder rights · Amended charter or bylaws · Other material eventMar 13, 2025
- Regulation FD disclosureMar 6, 2025
- Entered a material agreement · Results of operations · Regulation FD disclosure · Other material eventFeb 6, 2025
- Terminated a material agreementJan 31, 2025
- Other material eventJan 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GJun 9, 2025
- SCHEDULE 13D/AMay 27, 2025
- 4May 23, 2025
- SCHEDULE 13D/AMay 23, 2025
- SCHEDULE 13G/AMay 23, 2025
- 4FORM 4May 23, 2025
- 4FORM 4May 23, 2025
- 4FORM 4May 23, 2025
- 4FORM 4May 23, 2025
- 4FORM 4May 23, 2025
- 4FORM 4May 23, 2025
- 4FORM 4May 23, 2025
- 4FORM 4May 23, 2025
- 4FORM 4May 23, 2025
- 4FORM 4May 23, 2025
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.